Business Wire

Personalis Announces a Partnership with Berry Genomics for China Expansion

MENLO PARK, Calif.–(BUSINESS WIRE)–#PrecisionOncology–Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced the partnership with Berry Genomics, headquartered in the People’s Republic of China.

Personalis will be expanding business operations in the People’s Republic of China in 2020, and plans to form a wholly-owned subsidiary in Shanghai. The expansion will include building out a laboratory operation for local customers to use its ImmunoID NeXT PlatformTM, a commercial team to support local customers, and general and administrative functions.

Under terms of the agreement, Berry Genomics will provide Personalis certain services and local support.

“I’m pleased to be able to announce our partnership with the highly regarded Berry Genomics, headquartered in the PRC,” said John West, Chief Executive Officer. “Having achieved a high degree of scale in our Menlo Park, CA operation, we are poised to expand globally and entering into a partnership with a company that has the track record and capabilities of Berry Genomics will help us accelerate the ramp-up of our operation. Both companies have benefited from experience founded in the origin of next generation sequencing, and together we will take it even further.”

“We are excited to partner with Personalis, who is very well known for transforming the development of next-generation cancer therapies by providing more comprehensive molecular data,” said Dr. Daixing Zhou, Chief Executive Officer of Berry Genomics. “We have been focusing on disease detection and elucidating underlying molecular mechanisms. This partnership will serve the pharmaceutical community and ultimately enable them to develop better therapeutics, a natural extension of our current business.”




Related Articles

Back to top button